While semaglutide does not require dose adjustment for mild to moderate renal impairment, experience in patients with severe renal impairment is limited
This leads to muscle loss, metabolic slowdown, and a disappointing body composition even when the scale moves in the right direction
Real-world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network
Compounded medications, such as Semaglutide/Cyanocobalamin, are not FDA-approved medications, and FDA does not review compounded medications for safety or efficacy
Ozempic is also indicated to reduce cardiovascular risk in adults with T2D and established cardiovascular disease, while Wegovy is indicated for cardiovascular risk reduction in adults with established cardiovascular disease who have overweight or obesity